109 results on '"Raffa, R. B."'
Search Results
2. The fentanyl family: A distinguished medical history tainted by abuse
3. The “Darknet”: The new street for street drugs
4. Cebranopadol: novel dual opioid/NOP receptor agonist analgesic
5. The evolving understanding of the analgesic mechanism of action of flupirtine
6. Cancer ‘survivor-care’: I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment
7. A proposed mechanism for chemotherapy-related cognitive impairment (‘chemo-fog’)
8. Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example
9. What do we (not) know about how paracetamol (acetaminophen) works?
10. Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced ‘chemo-fog’
11. Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in ‘chemo-fog’/’chemo-brain’
12. The M5 muscarinic receptor as possible target for treatment of drug abuse
13. Critical review of ropinirole and pramipexole – putative dopamine D3-receptor selective agonists – for the treatment of RLS
14. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies
15. Basic pharmacology relevant to drug abuse assessment: tramadol as example
16. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use
17. Is ‘chemo-fog’/‘chemo-brain’ caused by cancer chemotherapy?
18. A potential novel strategy to separate therapeutic- and side-effects that are mediated via the same receptor: β-arrestin2/G-protein coupling antagonists
19. A second (non-genomic) steroid mechanism of action: possible opportunity for novel pharmacotherapy?
20. Potential novel targets for Alzheimer pharmacotherapy: I. Secretases
21. Could a common biochemical mechanism underlie addictions?
22. Substance P antagonists: the next breakthrough in treating depression?
23. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities
24. Cebranopadol: novel dual opioid/NOP receptor agonist analgesic
25. The Centers for Disease Control and Prevention opioid guidelines: potential for unintended consequences and will they be abused?
26. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?
27. The role of abuse-deterrent formulations in countering opioid misuse and abuse
28. Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs
29. Delta opioid agonists: a concise update on potential therapeutic applications
30. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression
31. The clinical analgesic efficacy of buprenorphine
32. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches
33. A modern analgesics pain ‘pyramid’
34. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
35. Cancer ‘survivor-care’: II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment)
36. Vitamin D and type 2 diabetes mellitus
37. Implications of climate change (global warming) for the healthcare system
38. CB1-independent mechanisms of Δ9-THCV, AM251 and SR141716 (rimonabant)
39. A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia
40. Multi-mechanistic analgesia for opioid-induced hyperalgesia
41. The evolving understanding of the analgesic mechanism of action of flupirtine
42. Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example
43. A proposed mechanism for chemotherapy-related cognitive impairment (‘chemo-fog’)
44. Cancer ‘survivor-care’: I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment
45. Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in âchemo-fogâ/âchemo-brainâ
46. The M5muscarinic receptor as possible target for treatment of drug abuse
47. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic use
48. A potential novel strategy to separate therapeutic- and side-effects that are mediated via the same receptor: beta-arrestin2/G-protein coupling antagonists
49. Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally
50. Pharmacology of oral combination analgesics: rational therapy for pain
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.